4D Molecular Therapeutics, Inc. Research and Development Expense
4D Molecular Therapeutics, Inc. (FDMT) reported Research and Development Expense of $15.84 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-11-10
- 4D Molecular Therapeutics, Inc. research and development expense for the quarter ending 2021-09-30 was $15.84M, a 37.08% increase year-over-year.
- 4D Molecular Therapeutics, Inc. research and development expense for the quarter ending 2021-06-30 was $15.22M, a 3.16% decline year-over-year.
- 4D Molecular Therapeutics, Inc. research and development expense for the quarter ending 2021-03-31 was $12.77M, a 2.96% decline year-over-year.
- 4D Molecular Therapeutics, Inc. research and development expense for the quarter ending 2020-09-30 was $11.55M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month |
|---|---|---|---|
| 2021-09-30 | $15.84M 10-Q · filed 2021-11-10 | $31.06M derived: sum of 2 quarters · filed 2021-11-10 | $43.83M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $15.22M 10-Q · filed 2021-08-12 | $27.99M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $12.77M 10-Q · filed 2021-05-13 | ||
| 2020-09-30 | $11.55M 10-Q · filed 2021-11-10 | $27.27M derived: sum of 2 quarters · filed 2021-11-10 | $40.43M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $15.72M 10-Q · filed 2021-08-12 | $28.88M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $13.16M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |